Company: SHPH
Filing Date: 2025-11-18
Form Type: S-1
Source: 0001493152-25-024089
Chunk: 20

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-11-18
Form: S-1
Chunk 20
---
| 10.74 
 10.75 |     | Securities Purchase Agreement, dated June 20, 2025 (incorporated by reference to 8-K filed June 25, 2025)                 
 Registration Rights Agreement, dated June 20, 2025 (incorporated by reference to 8-K filed June 25, 2025)                 |
|:------|:----|:--------------------------------------------------------------------------------------------------------------------------|
| 10.76 |     | Consulting Agreement, dated September 15, 2025 (incorporated by reference to 8-K filed September 22, 2025)                |
| 10.77 |     | Binding Term Sheet between the Company and Molecule (incorporated by reference to 8-K filed October 21, 2025)             |
| 10.78 |     | Form of Securities Purchase Agreement, dated November 3, 2025 (incorporated by reference to 8-K filed November 7, 2025)   |
| 10.79 |     | Placement Agency Agreement, dated November 3, 2025 (incorporated by reference to 8-K filed November 7, 2025)              |
| 21    |     | List of Subsidiaries (incorporated by reference to Exhibit 21 to the Annual Report on Form 10-K filed on March 21, 2024). |
| 23.1* |     | Consent of Forvis Mazars, LLP                                                                                             |
| 23.2* |     | Consent of Sullivan & Worcester LLP (included in Exhibit 5.1)                                                             |
| 24    |     | Power of Attorney (included in the signature page to this registration statement).                                        |
| 107*  |     | Filing Fee Table                                                                                                          |

+Certain portions of this exhibit have been redacted in accordance with Item 601(b)(10)(iv) because such information (i) is deemed not material and (ii) is of the type of information that the Company normally treats as private or confidential.

* Filed herewith

(b) Financial statement schedules

Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.

Item 17. Undertakings

The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective